Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Oncogenesis is Scopus-indexed (Q1, CiteScore 11), WoS SCIE, DOAJ. Published by Springer Nature.
Checked against the index lists dated .
ISSN 2157-9024Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Molecular Biology | 60 / 414 | 85th | Q1 |
| Cancer Research | 41 / 233 | 82nd | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q1, CiteScore 11.
Oncogenesis is Q1 in Molecular Biology (rank 60 of 414) and Q1 in Cancer Research (rank 41 of 233), by CiteScore 2025.
Oncogenesis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11, which places it in quartile Q1 at the 85th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.081, quartile Q1, with an H-index of 78.
The publisher lists an article processing charge of about US$4,290 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Oncogenesis is published by Springer Nature. Its ISSN is 2157-9024.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Oncogenesis has an h-index of 94 and a 2-year mean of 4.31 citations per paper (OpenAlex). Its Scopus CiteScore is 11, quartile Q1. On 2-year citations it ranks #109 of 411 Scopus journals in Molecular Biology.
Oncogenesis published 51 papers in 2025; its busiest recent year was 2017 with 108. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (40.4%), United States (15.7%) and Taiwan (7.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 16 retracted papers are recorded (15.7 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.